NCT05722795 (I-CONIC) is a NA clinical trial of Imatinib 400 MG Oral Tablet in Breast Cancer, sponsored by Vastra Gotaland Region.

Who is sponsoring NCT05722795?

NCT05722795 is sponsored by Vastra Gotaland Region.

What drugs are being tested in NCT05722795?

Interventions in NCT05722795: Imatinib 400 MG Oral Tablet.

What condition does NCT05722795 study?

NCT05722795 studies Breast Cancer, Triple Negative Breast Cancer.

Is NCT05722795 still recruiting?

NCT05722795 is currently recruiting now. Last updated 9 July 2025.

Last reviewed 2025-07-09 · How we verify

NCT05722795: I-CONIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)

Recruiting now NA Last updated 9 July 2025

What this trial tests

NA trial testing Imatinib 400 MG Oral Tablet in Breast Cancer in 40 participants. Currently enrolling.

Timeline

1 June 2023

Primary endpoint
28 June 2029

28 December 2029

Quick facts

Lead sponsor	Vastra Gotaland Region
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	40
Start date	1 June 2023
Primary completion	28 June 2029
Estimated completion	28 December 2029
Sites	1 location across Sweden

Drugs / interventions tested

Imatinib 400 MG Oral Tablet

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →

Sponsor

Vastra Gotaland Region — full company profile →

Who can join

18 and older, any sex, with Breast Cancer or Triple Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single centre Window-of-Opportunity trial investigating the efficacy and feasibility of short term imatinib in patients with newly diagnosed triple negative breast cancer (TNBC) planned for surgery, with tumours ≥ 15 mm, any status in the axilla when neoadjuvant treatment not is considered as an option. The primary aim is to determine the proportion of patients that converts to estrogen receptor (ER) positive breast cancer in the removed breast cancer tissue at surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence.
Reid SE, Pantaleo J, Bolivar P, Bocci M, et al · · 2024 · cited 18× · PMID 38388711 · DOI 10.1038/s41388-024-02973-x

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Vastra Gotaland Region trials

Trials by the same sponsor.

NCT07430865 — The RECOVER Study - Postpartum Recovery of Pelvic Floor Structures and the Impact of Early Rehabilitation · NA · recruiting
NCT07472335 — Home-based Acute Care for Older Persons Initiated by the Emergency Medical and Ambulance Services - a Retrospective Obse · not yet recruiting
NCT07246577 — The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant C · recruiting
NCT07449338 — Prospective Cohort Study of Response and Tolerability of Accelerated Intermittent Theta-burst Stimulation (1W-AiTBS) · not yet recruiting
NCT07334340 — Modified vs Standard CDED: Evaluation of a Nordic Adaptation of Nutritional Therapy in Paediatric Crohn's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05722795 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vastra Gotaland Region
Last refreshed: 9 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05722795.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing